Pharmacogenetic testing in Italy: results of a nationwide survey by the Joint Working Group for the pharmacogenetics implementation in Italy - PubMed
6 hours ago
- #Italy survey
- #oncology testing
- #pharmacogenetics
- Pharmacogenetic testing in Italy is primarily conducted in public institutions, with 82% based in general or research hospitals.
- Testing focuses on oncology, specifically DPYD (94%) and UGT1A1 (84%) for fluoropyrimidine and irinotecan therapies.
- There is high adherence to national (SIF/AIOM) and international (CPIC/DPWG) guidelines, but variable compliance with AMP Tier 1 analytical standards.
- Pharmacological counseling is limited, offered by only 29% of laboratories, mainly through clinical pharmacology units.
- Marked geographical disparities exist, with pharmacogenetic activity concentrated in Northern Italy, indicating inequitable access.
- The survey highlights a need for a coordinated national framework to standardize practices and ensure evidence-based pharmacogenetic care.